-
Mashup Score: 1Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma - 2 year(s) ago
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma - 2 year(s) ago
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory
-
-
Mashup Score: 3Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma - 2 year(s) ago
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory https://t.co/QecvdfLdoE
-
-
Mashup Score: 7Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma - 2 year(s) ago
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory https://t.co/0NCYxCzNYZ
-
-
Mashup Score: 7
Purpose We aim to assess attitudes toward a COVID-19 vaccine and vaccination status in cancer patients and to explore additional factors such as the level of information and comprehensibility and accessibility of this information, anxiety symptoms in general and toward COVID-19, and general health literacy. Methods We included 425 outpatients (mean age 61.4, age range 30–88 years, 60.5% women) of…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey [Feb 26, 2022] Heyne et al. J Cancer Research Clin Oncol https://t.co/TLldxOTrtB #COVDID19nCancer #COVDI19Vaccine #CCC19 #COVID19 https://t.co/PWVJISp60Z
-
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma [Mar 8, 2022] @AjayNookaMD et al. @JCO_ASCO https://t.co/nFlGvojgGz #mmsm #COVDID19nCancer #COVID19Vaccine #COVID19 #IDonc @WinshipAtEmory https://t.co/75jg1cN1zr